Combining immunomodulators and antivirals for COVID-19 - Authors' reply

Raquel Almansa; Ana P Tedim; Amanda de la Fuente; Jose María Eiros; David J Kelvin; Antoni Torres; Jesus F Bermejo-Martin

doi:10.1016/S2666-5247(21)00115-4

Combining immunomodulators and antivirals for COVID-19 - Authors' reply

Lancet Microbe. 2021 Jun;2(6):e234. doi: 10.1016/S2666-5247(21)00115-4. Epub 2021 Jun 2.

Authors

Raquel Almansa^{1

2

3}, Ana P Tedim^{1

2}, Amanda de la Fuente^{1

2}, Jose María Eiros^{4

2}, David J Kelvin^{5

6}, Antoni Torres^{3

7}, Jesus F Bermejo-Martin^{1

3}

Affiliations

¹ Group for Biomedical Research in Sepsis, Instituto de Investigación Biomédica de Salamanca, Gerencia Regional de Salud, Paseo de San Vicente, 37007 Salamanca, Spain.
² Research Unit, Hospital Universitario Río Hortega, Gerencia Regional de Salud, Valladolid, Spain.
³ Centro de Investigación Biomédica en Red en Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
⁴ Microbiology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud, Valladolid, Spain.
⁵ Department of Microbiology and Immunology, Faculty of Medicine, Canadian Center for Vaccinology, Dalhousie University, Halifax, NS, Canada.
⁶ Laboratory of Immunity, Shantou University Medical College, Jinping, Shantou, Guangdong, China.
⁷ Department of Pulmonology, Hospital Clinic de Barcelona, Universidad de Barcelona, Institut D investigacions August Pi I Sunyer, Barcelona, Spain.

No abstract available

Publication types

Letter
Comment

MeSH terms

Adjuvants, Immunologic
Antiviral Agents / therapeutic use
COVID-19 Drug Treatment*
Dermatologic Agents*
Humans
Immunologic Factors / therapeutic use
SARS-CoV-2

Substances

Adjuvants, Immunologic
Antiviral Agents
Dermatologic Agents
Immunologic Factors